An analysis of 600 biotech readouts shows a market upswing led by small-cap companies (under $1B). The rate of positive stock movement after data releases surged from 30% in the first half of the year to 70% in the third quarter, signaling renewed investor confidence and momentum.
Two major cardiovascular trials targeting novel biomarkers (LPA and hs-CRP) failed to improve outcomes despite successfully lowering the biomarkers. This has dampened enthusiasm for novel targets and shifted R&D and investor focus back to established, "unsexy" pathways like PCSK9, GLP-1, and SGLT2, which are now viewed as less risky.
The in vivo CAR-T field is not a "winner-takes-all" market. A strategic split is emerging, reflected in Big Pharma M&A. Reversible, finite-exposure RNA-based therapies are preferred for autoimmune diseases due to safety, while more permanent lentiviral vectors are reserved for high-risk oncology indications.
Following positive news from a competitor, an upcoming catalyst that may have gone unnoticed is Incyte's first-line pancreatic data for its KRAS G12D inhibitor. While preliminary data leaked, the full six-month follow-up results, expected at the ESMO conference, could be a significant inflection point for the company and the treatment landscape.